Perry NisenFounder

United States - San Diego County, California

I am currently CEO of Quanta Therapeutics, Executive Partner with Sofinnova Investments, a member of the Board of Directors of Teva Pharmaceuticals and several Scientific Advisory Boards.

Quanta Therapeutics targets RAS which has the highest frequency of mutation of any oncogene in human cancer. Quanta is pioneering allosteric modulation to directly restore conformational control of active RAS signaling at the cell membrane to inhibit the full scope of RAS-driven cancer types. Our team applies deep biologic insight, unique protein conformation detection technology and sophisticated medicinal chemistry expertise to develop novel small molecules as first-in-class precision medicines breaking the resistance paradigms of targeted therapy in oncology.

I'm the former CEO and Donald Bren Chief Executive Chair of the Sanford Burnham Prebys Medical Discovery Institute. Previously, I was Senior Vice President, Science and Innovation at GlaxoSmithKline and held leadership roles as interim Chief Medical Officer, Senior Vice President and Head of Oncology Research and Development, and of Clinical Pharmacology and Discovery Medicine. In those roles I contributed to the successful discovery and development of multiple marketed products. I was a member of key governance, scientific advisory and investment Boards at GlaxoSmithKline. My leadership helped establish an end-to-end research and development center in China. I also held positions as the Lowe Foundation Professor of Neuro-Oncology at the University of Texas Southwestern School of Medicine, Division Vice President, Cancer Research and Oncology Development at Abbott Laboratories. I hold a B.S. from Stanford University and M.D. and Ph.D from the Albert Einstein College of Medicine.